Multiple retrospective studies using the MCAM/CSPG4 CellSearch® Kit have found that CTC levels detected at baseline correlates with overall survival in late-stage melanoma (Rao et al., 2011; Khoja et al., 2013; Bidard et al., 2014) (Table 1). Here, CSPG4 is linked to melanoma.